Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran monotherapy in Chinese adults with elevated LDL-C
NCT05888103Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2023
- Primary completion
- Apr 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in hypercholesterolemia, mixed dyslipidemia, sponsored by Novartis. Started Jul 2023; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT05888103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05888103.